1. Home
  2. GSIW vs GTBP Comparison

GSIW vs GTBP Comparison

Compare GSIW & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIW
  • GTBP
  • Stock Information
  • Founded
  • GSIW 2016
  • GTBP 1965
  • Country
  • GSIW Hong Kong
  • GTBP United States
  • Employees
  • GSIW N/A
  • GTBP N/A
  • Industry
  • GSIW
  • GTBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSIW
  • GTBP Health Care
  • Exchange
  • GSIW Nasdaq
  • GTBP Nasdaq
  • Market Cap
  • GSIW 12.3M
  • GTBP 4.9M
  • IPO Year
  • GSIW 2023
  • GTBP N/A
  • Fundamental
  • Price
  • GSIW $0.56
  • GTBP $2.14
  • Analyst Decision
  • GSIW
  • GTBP Strong Buy
  • Analyst Count
  • GSIW 0
  • GTBP 1
  • Target Price
  • GSIW N/A
  • GTBP $11.00
  • AVG Volume (30 Days)
  • GSIW 11.3M
  • GTBP 238.1K
  • Earning Date
  • GSIW 12-31-2024
  • GTBP 03-25-2025
  • Dividend Yield
  • GSIW N/A
  • GTBP N/A
  • EPS Growth
  • GSIW N/A
  • GTBP N/A
  • EPS
  • GSIW N/A
  • GTBP N/A
  • Revenue
  • GSIW $1,313,795.00
  • GTBP N/A
  • Revenue This Year
  • GSIW N/A
  • GTBP N/A
  • Revenue Next Year
  • GSIW N/A
  • GTBP N/A
  • P/E Ratio
  • GSIW N/A
  • GTBP N/A
  • Revenue Growth
  • GSIW N/A
  • GTBP N/A
  • 52 Week Low
  • GSIW $0.43
  • GTBP $1.72
  • 52 Week High
  • GSIW $15.45
  • GTBP $10.66
  • Technical
  • Relative Strength Index (RSI)
  • GSIW 49.76
  • GTBP 42.94
  • Support Level
  • GSIW $0.44
  • GTBP $2.10
  • Resistance Level
  • GSIW $1.25
  • GTBP $2.39
  • Average True Range (ATR)
  • GSIW 0.11
  • GTBP 0.21
  • MACD
  • GSIW 0.01
  • GTBP 0.01
  • Stochastic Oscillator
  • GSIW 18.62
  • GTBP 36.00

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: